{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:39:20Z","timestamp":1763663960250,"version":"3.45.0"},"reference-count":39,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T00:00:00Z","timestamp":1763596800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"iNOVA4Health","award":["10.54499\/UIDB\/04462\/2020"],"award-info":[{"award-number":["10.54499\/UIDB\/04462\/2020"]}]},{"name":"iNOVA4Health","award":["10.54499\/UIDP\/04462\/2020"],"award-info":[{"award-number":["10.54499\/UIDP\/04462\/2020"]}]},{"name":"LS4FUTURE Associated Laboratory","award":["10.54499\/LA\/P\/0087\/2020"],"award-info":[{"award-number":["10.54499\/LA\/P\/0087\/2020"]}]},{"name":"iBETXplore program"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:p>Multispecific antibodies (MsAbs) enable the targeting of different epitopes, representing a strategy with enhanced therapeutic potential. However, the intracellular assembly of MsAbs is complex and generates unwanted mispaired species, imposing a significant burden on downstream processing and analytical characterization, thus increasing the overall timeline and cost of bioprocess development. The establishment of analytical tools to aid in the characterization and understanding of MsAb mispairing profiles at early-stage screenings is mandatory. Here, we implemented mass spectrometry (MS) and high-performance liquid chromatography (HPLC) methods to assess mispairing levels using several Chinese Hamster Ovary (CHO) clones producing a MsAb. Results showed that both methods are suitable to be explored in early-stage screenings enabling the identification of higher quality MsAb producer clones. Importantly, not only protein A-purified but also clarified samples can be analysed by the methods established, streamlining the characterization process and reducing costs and analysis time. Moreover, we evaluated the impact of different mispairing levels on antibody functionality by biophysical tools. Nano-Differential Scanning Fluorometry (nDSF) was used to record thermal stability profiles and Surface Plasmon Resonance (SPR) to infer on the binary interactions established with three different antigens, revealing distinct profiles between groups with higher and lower mispairing levels. Our work allowed the development and implementation of a mispairing analytical toolbox, critical for early-stage screening and deeper characterization of these complex biopharmaceuticals.<\/jats:p>","DOI":"10.1371\/journal.pone.0336791","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:27:12Z","timestamp":1763663232000},"page":"e0336791","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Multispecific antibodies: Bioanalytics for early-stage screening and characterization of mispairing profiles"],"prefix":"10.1371","volume":"20","author":[{"given":"Catarina","family":"Melo","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5000-7217","authenticated-orcid":true,"given":"Sofia B.","family":"Carvalho","sequence":"additional","affiliation":[]},{"given":"Maria J.","family":"Sebasti\u00e3o","sequence":"additional","affiliation":[]},{"given":"Ricardo A.","family":"Gomes","sequence":"additional","affiliation":[]},{"given":"Pedro M. F.","family":"Sousa","sequence":"additional","affiliation":[]},{"given":"Patr\u00edcia","family":"Gomes-Alves","sequence":"additional","affiliation":[]}],"member":"340","published-online":{"date-parts":[[2025,11,20]]},"reference":[{"issue":"3","key":"pone.0336791.ref001","doi-asserted-by":"crossref","first-page":"220","DOI":"10.7861\/clinmedicine.17-3-220","article-title":"Developments in therapy with monoclonal antibodies and related proteins","volume":"17","author":"HM Shepard","year":"2017","journal-title":"Clin Med (Lond)"},{"issue":"16","key":"pone.0336791.ref002","doi-asserted-by":"crossref","first-page":"5909","DOI":"10.1074\/jbc.RA118.001752","article-title":"A biparatopic agonistic antibody that mimics fibroblast growth factor 21 ligand activity","volume":"293","author":"SY Shi","year":"2018","journal-title":"J Biol Chem"},{"issue":"5","key":"pone.0336791.ref003","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1038\/s41375-018-0014-3","article-title":"Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation","volume":"32","author":"CE Correnti","year":"2018","journal-title":"Leukemia"},{"issue":"5","key":"pone.0336791.ref004","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3109\/10428194.2016.1161185","article-title":"Blinatumomab: a CD19\/CD3 bispecific T cell engager (BiTE) with unique anti-tumor efficacy","volume":"57","author":"M-E Goebeler","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"pone.0336791.ref005","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2017.12.002","article-title":"Bispecific antibodies for cancer therapy: a review","volume":"185","author":"A Krishnamurthy","year":"2018","journal-title":"Pharmacol Therapeutics"},{"key":"pone.0336791.ref006","doi-asserted-by":"crossref","DOI":"10.1186\/s10020-018-0051-4","article-title":"Bi-specific and tri-specific antibodies- the next big thing in solid tumor therapeutics","volume":"24","author":"K Runcie","year":"2018","journal-title":"Mol Med"},{"key":"pone.0336791.ref007","doi-asserted-by":"crossref","DOI":"10.4161\/mabs.2.2.11221","article-title":"Catumaxomab: clinical development and future directions","volume":"2","author":"R Linke","year":"2010","journal-title":"mAbs"},{"issue":"9","key":"pone.0336791.ref008","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJMoa1609783","article-title":"Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia","volume":"376","author":"H Kantarjian","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"pone.0336791.ref009","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1158\/1078-0432.CCR-18-2337","article-title":"FDA approval: blinatumomab for patients with b-cell precursor acute lymphoblastic leukemia in morphologic remission with minimal residual disease","volume":"25","author":"EY Jen","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10","key":"pone.0336791.ref010","doi-asserted-by":"crossref","DOI":"10.1177\/2040620718799997","article-title":"The role of emicizumab, a bispecific factor IXa- and factor X-directed antibody, for the prevention of bleeding episodes in patients with hemophilia A","volume":"9","author":"T Knight","year":"2018","journal-title":"Ther Adv Hematol"},{"issue":"17","key":"pone.0336791.ref011","doi-asserted-by":"crossref","first-page":"3262","DOI":"10.1158\/1078-0432.CCR-22-3713","article-title":"FDA approval summary: amivantamab for the treatment of patients with non-small cell lung cancer with EGFR exon 20 insertion mutations","volume":"29","author":"K Chon","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"23","key":"pone.0336791.ref012","doi-asserted-by":"crossref","first-page":"5190","DOI":"10.1158\/1078-0432.CCR-22-2108","article-title":"A novel B7-H6-Targeted IgG-Like T cell-engaging antibody for the treatment of gastrointestinal tumors","volume":"28","author":"W Zhang","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"13","key":"pone.0336791.ref013","doi-asserted-by":"crossref","first-page":"3430","DOI":"10.3390\/cancers15133430","article-title":"Tebentafusp in patients with metastatic uveal melanoma: a real-life retrospective multicenter study","volume":"15","author":"D Tomsitz","year":"2023","journal-title":"Cancers (Basel)"},{"key":"pone.0336791.ref014","doi-asserted-by":"crossref","first-page":"2861","DOI":"10.2147\/DDDT.S427416","article-title":"Faricimab: transforming the future of macular diseases treatment - a comprehensive review of clinical studies","volume":"17","author":"GD Panos","year":"2023","journal-title":"Drug Des Devel Ther"},{"issue":"19","key":"pone.0336791.ref015","doi-asserted-by":"crossref","DOI":"10.1158\/1078-0432.CCR-23-2591","article-title":"AACR cancer progress report 2023: advancing the frontiers of cancer science and medicine","volume":"29","author":"PA Williams","year":"2023","journal-title":"Clin Cancer Res"},{"issue":"24","key":"pone.0336791.ref016","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.1056\/NEJMoa2204591","article-title":"Talquetamab, a T-Cell-Redirecting GPRC5D Bispecific Antibody for Multiple Myeloma","volume":"387","author":"A Chari","year":"2022","journal-title":"N Engl J Med"},{"issue":"5","key":"pone.0336791.ref017","doi-asserted-by":"crossref","first-page":"660","DOI":"10.1080\/10428194.2024.2313628","article-title":"A matching-adjusted indirect comparison of the efficacy of elranatamab versus teclistamab in patients with triple-class exposed\/refractory multiple myeloma","volume":"65","author":"I Mol","year":"2024","journal-title":"Leuk Lymphoma"},{"issue":"1","key":"pone.0336791.ref018","doi-asserted-by":"crossref","first-page":"26","DOI":"10.17145\/jab.20.005","article-title":"Engineered technologies and bioanalysis of multispecific antibody formats","volume":"6","author":"M Amaral","year":"2020","journal-title":"J Appl Bioanal"},{"issue":"8","key":"pone.0336791.ref019","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1093\/protein\/gzq034","article-title":"VH\/VL interface engineering to promote selective expression and inhibit conformational isomerization of thrombopoietin receptor agonist single-chain diabody","volume":"23","author":"T Igawa","year":"2010","journal-title":"Protein Eng Des Sel"},{"key":"pone.0336791.ref020","doi-asserted-by":"crossref","DOI":"10.1080\/19420862.2021.1967714","article-title":"Ten years in the making: application of CrossMab technology for the development of therapeutic bispecific antibodies and antibody fusion proteins","volume":"13","author":"M Surowka","year":"2021","journal-title":"mAbs"},{"key":"pone.0336791.ref021","first-page":"451","article-title":"Challenges and strategies for next-generation bispecific antibody-based antitumor therapeutics","volume-title":"Cellular and Molecular Immunology","author":"H Li","year":"2020"},{"key":"pone.0336791.ref022","doi-asserted-by":"crossref","first-page":"1063002","DOI":"10.3389\/fimmu.2022.1063002","article-title":"Generation of bispecific antibodies by structure-guided redesign of IgG constant regions","volume":"13","author":"YW Iwasaki","year":"2023","journal-title":"Front Immunol"},{"issue":"3","key":"pone.0336791.ref023","doi-asserted-by":"crossref","first-page":"2764","DOI":"10.1021\/acs.analchem.9b05018","article-title":"Intact protein mass spectrometry of cell culture harvest guides cell line development for trispecific antibodies","volume":"92","author":"F Tousi","year":"2020","journal-title":"Anal Chem"},{"issue":"1","key":"pone.0336791.ref024","doi-asserted-by":"crossref","DOI":"10.1002\/btpr.2720","article-title":"An integrated approach to aggregate control for therapeutic bispecific antibodies using an improved three column mab platform-like purification process","volume":"35","author":"C Andrade","year":"2019","journal-title":"Biotechnol Prog"},{"issue":"11","key":"pone.0336791.ref025","doi-asserted-by":"crossref","first-page":"2890","DOI":"10.3390\/biomedicines11112890","article-title":"Identification of mispairing omic signatures in chinese hamster ovary (CHO) cells producing a tri-specific antibody","volume":"11","author":"MJ Sebasti\u00e3o","year":"2023","journal-title":"Biomedicines"},{"issue":"8","key":"pone.0336791.ref026","doi-asserted-by":"crossref","first-page":"1226","DOI":"10.1080\/19420862.2018.1511198","article-title":"A systematic approach for analysis and characterization of mispairing in bispecific antibodies with asymmetric architecture","volume":"10","author":"C Wang","year":"2018","journal-title":"MAbs"},{"issue":"1","key":"pone.0336791.ref027","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s43018-019-0004-z","article-title":"Trispecific antibodies enhance the therapeutic efficacy of tumor-directed T cells through T cell receptor co-stimulation","volume":"1","author":"L Wu","year":"2020","journal-title":"Nat Cancer"},{"issue":"5","key":"pone.0336791.ref028","doi-asserted-by":"crossref","first-page":"1131","DOI":"10.1002\/btpr.1767","article-title":"Free light chain content in culture media reflects recombinant monoclonal antibody productivity and quality","volume":"29","author":"P Bhoskar","year":"2013","journal-title":"Biotechnol Prog"},{"key":"pone.0336791.ref029","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.jbiotec.2013.03.019","article-title":"Control of IgG LC:HC ratio in stably transfected CHO cells and study of the impact on expression, aggregation, glycosylation and conformational stability","volume":"165","author":"SCL Ho","year":"2013","journal-title":"J Biotechnol"},{"issue":"3","key":"pone.0336791.ref030","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/antib7030029","article-title":"Tuning relative polypeptide expression to optimize assembly, yield and downstream processing of bispecific antibodies","volume":"7","author":"G Magistrelli","year":"2018","journal-title":"Antibodies (Basel)"},{"issue":"10","key":"pone.0336791.ref031","doi-asserted-by":"crossref","first-page":"3744","DOI":"10.1002\/bit.27850","article-title":"Expression liabilities in a four-chain bispecific molecule","volume":"118","author":"C Guo","year":"2021","journal-title":"Biotechnol Bioeng"},{"key":"pone.0336791.ref032","doi-asserted-by":"crossref","DOI":"10.1016\/j.ab.2020.113909","article-title":"Mechanism of antibodies purification by protein A","volume-title":"Analytical Biochemistry","author":"M Zarrineh","year":"2020"},{"key":"pone.0336791.ref033","doi-asserted-by":"crossref","DOI":"10.1016\/B978-0-08-103019-6.00008-4","article-title":"A roadmap for IgG-like bispecific antibody purification","volume-title":"Approaches to the Purification, Analysis and Characterization of Antibody-Based Therapeutics","author":"Y Li","year":"2020"},{"issue":"4","key":"pone.0336791.ref034","doi-asserted-by":"crossref","first-page":"852","DOI":"10.4161\/mabs.28693","article-title":"Separation of mAbs molecular variants by analytical hydrophobic interaction chromatography HPLC: overview and applications","volume":"6","author":"M Haverick","year":"2014","journal-title":"MAbs"},{"key":"pone.0336791.ref035","doi-asserted-by":"crossref","first-page":"124085","DOI":"10.1016\/j.jchromb.2024.124085","article-title":"Identification and quantification of chain-pairing variants or mispaired species of asymmetric monovalent bispecific IgG1 monoclonal antibody format using reverse-phase polyphenyl chromatography coupled electrospray ionization mass spectrometry","volume":"1237","author":"R Poskute","year":"2024","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"issue":"2","key":"pone.0336791.ref036","doi-asserted-by":"crossref","DOI":"10.1002\/jps.23405","article-title":"High-throughput melting-temperature analysis of a monoclonal antibody by differential scanning fluorimetry in the presence of surfactants","volume":"102","author":"T Menzen","year":"2013","journal-title":"J Pharm Sci"},{"key":"pone.0336791.ref037","volume-title":"Thermal Unfolding nanoDSF Thermal Unfolding Analysis of Proteins Without Tryptophan Residues. NT-PR-007","author":"V Misetic","year":"2016"},{"key":"pone.0336791.ref038","doi-asserted-by":"crossref","DOI":"10.1007\/978-0-387-46312-4","volume-title":"Principles of fluorescence spectroscopy. Principles of Fluorescence Spectroscopy","author":"JR Lakowicz","year":"2006"},{"key":"pone.0336791.ref039","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.jpba.2014.09.007","article-title":"Development and validation of a novel SPR-based assay principle for bispecific molecules","volume":"102","author":"C Gassner","year":"2015","journal-title":"J Pharm Biomed Anal"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336791","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T18:27:18Z","timestamp":1763663238000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0336791"}},"subtitle":[],"editor":[{"given":"Alessio","family":"Branchini","sequence":"first","affiliation":[]}],"short-title":[],"issued":{"date-parts":[[2025,11,20]]},"references-count":39,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2025,11,20]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0336791","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,20]]}}}